NanoViricides and CDC collaborate in rabies treatment study

The study, to be performed in collaboration with the US Centers for Disease Control and Prevention (CDC) Rabies program, is scheduled to begin soon. This study will expand on two successful animal studies of RabiCide-I performed previously by the government of Vietnam.

Anil Diwan, president of NanoViricides, said: “Collaborating with CDC in designing and conducting these studies is an important step forward. If the current studies are successful, we anticipate that this will be instrumental in helping our anti-rabies nanoviricide towards drug approval and widespread use across the world.”